Kevin Bitterman biography

Kevin J. Bitterman Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Bitterman currently serves as a partner at venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June 2017, Dr. Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr. Bitterman was also the founding CEO at Editas Medicine Inc., a pharmaceutical company, Visterra Inc., a biotechnology company, and Morphic Rock, LLC, a biotechnology company. During the past five years, Dr. Bitterman has served on the board of directors of Editas Medicine, Inc., Kala Pharmaceuticals, Inc., a pharmaceutical company, Genocea Biosciences, Inc., a biosciences company, as well as on the board of directors of several private companies. Dr. Bitterman also serves as board chair of the New England Venture Capital Association. Dr. Bitterman received a B.A. in biology from Rutgers College and a Ph.D. in genetics from Harvard Medical School.

What is the salary of Kevin Bitterman?

As the Non-Executive Independent Director of Akero Therapeutics Inc, the total compensation of Kevin Bitterman at Akero Therapeutics Inc is $379,579. There are 9 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.